ADVM Adverum Biotechnologies, Inc.

2.80
+0  (0%)
Previous Close 2.80
Open 2.85
Price To book 0.49
Market Cap 116.81M
Shares 41,718,000
Volume 418,956
Short Ratio 2.26
Av. Daily Volume 246,276

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 trial to be initiated 4Q 2017.
ADVM-043
Alpha-1 Antitrypsin (A1AT) Deficiency
Phase 2a negative data released June 2015 (met primary endpoint but increase in retinal thickness). As a result Phase 2b development will not proceed.
AVA-101
Wet age-related macular degeneration (Wet-AMD)

Latest News

  1. Adverum Biotechnologies to Present at Upcoming Investor Conferences
  2. ADVERUM BIOTECHNOLOGIES, INC. Files SEC form 8-K, Change in Directors or Principal Officers
  3. ADVERUM BIOTECHNOLOGIES, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule
  4. ADVERUM BIOTECHNOLOGIES, INC. Files SEC form 8-K, Change in Directors or Principal Officers
  5. Adverum Biotechnologies to Present At Phacilitate Cell & Gene Therapy World 2017
  6. Is KCAP Financial Inc (KCAP) A Good Stock to Buy?
  7. Is Osiris Therapeutics, Inc. (OSIR) A Good Stock To Buy?
  8. Is Adverum Biotechnologies Inc (ADVM) a Good Stock to Buy?
  9. ADVERUM BIOTECHNOLOGIES, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement
  10. ETFs with exposure to Adverum Biotechnologies, Inc. : December 5, 2016
  11. ADVERUM BIOTECHNOLOGIES, INC. Financials
  12. Adverum Biotechnologies, Inc. :ADVM-US: Earnings Analysis: Q3, 2016 By the Numbers : November 28, 2016
  13. Adverum Biotechnologies to Present at Upcoming Investor Conferences
  14. Adverum Biotechnologies, Inc. Reports Third Quarter 2016 Financial Results
  15. ADVERUM BIOTECHNOLOGIES, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
  16. Adverum (ADVM) Q3 Earnings Preview: What's in the Cards?
  17. ADVERUM BIOTECHNOLOGIES, INC. Files SEC form 8-K, Change in Directors or Principal Officers
  18. Adverum Biotechnologies, Inc. Announces New Executive Chair and CEO
  19. Adverum Biotechnologies Provides Update on Alpha-1 Antitrypsin Deficiency Program
  20. ADVERUM BIOTECHNOLOGIES, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure